Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

58
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
58
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

47
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
47
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

34
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
34
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

60
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
60
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

34
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges of Integrating Biosimilars Into Clinical Practice.

Journal of the advanced practitioner in oncology·2021
Same author

Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021
Same author

Alpelisib: A Novel Therapy for Patients With <i>PIK3CA-</i>Mutated Metastatic Breast Cancer.

Journal of the advanced practitioner in oncology·2021
Same author

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?

Journal of the advanced practitioner in oncology·2021
Same author

Determination of the Fair Market Value of Oncology Advanced Practitioners.

Journal of the advanced practitioner in oncology·2021
Same author

Oncology Advanced Practitioners and Breast Cancer Prevention.

Journal of the advanced practitioner in oncology·2021
Same journal

Retrospective Characterization of Specialized Palliative Care in Patients With Gliomas.

Journal of the advanced practitioner in oncology·2026
Same journal

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals.

Journal of the advanced practitioner in oncology·2026
Same journal

Building Bridges: The Impact of Medical Science Liaison and Advanced Practice Provider Collaborations.

Journal of the advanced practitioner in oncology·2026
Same journal

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy.

Journal of the advanced practitioner in oncology·2026
Same journal

Colorectal Cancer Treatment During Pregnancy.

Journal of the advanced practitioner in oncology·2026
Same journal

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.

Journal of the advanced practitioner in oncology·2026
See all related articles

Related Experiment Video

Updated: Nov 2, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Practical Considerations for Integrating Biosimilars Into Clinical Practice.

Megan B May1, Kate Deen Taucher2, Wendy H Vogel3

  • 1Baptist Health Lexington, Lexington, Kentucky.

Journal of the Advanced Practitioner in Oncology
|June 14, 2021
PubMed
Summary
This summary is machine-generated.

Oncology advanced practitioners must grasp biosimilar differences in efficacy, safety, and immunogenicity. Understanding cost-benefit and acceptance factors is crucial for successful oncology biosimilar adoption.

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.0K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.9K

Related Experiment Videos

Last Updated: Nov 2, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.0K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Practice

Background:

  • Innovator biologics and their subsequent biosimilars present unique challenges in oncology.
  • Understanding these differences is critical for effective patient care.

Purpose of the Study:

  • To outline the key differences between innovator biologics and biosimilars.
  • To guide oncology advanced practitioners (OAPs) in navigating biosimilar adoption factors.

Main Methods:

  • Literature review and synthesis of current evidence on biologic and biosimilar characteristics.
  • Analysis of factors influencing clinical decision-making and practice integration.

Main Results:

  • Key differences in efficacy, safety, and immunogenicity profiles require careful consideration.
  • Cost-benefit perceptions and clinician/patient acceptance significantly impact biosimilar uptake.

Conclusions:

  • OAPs need comprehensive knowledge of biosimilar nuances for informed practice.
  • Addressing perceived barriers is essential for the successful integration of biosimilars in oncology.